STOCKS TELEGRAPH

Tag: Hancock Jaffe Laboratories Inc

  • Top 15 Best Performing Medical Device Manufacture Companies Of 2020

    Top 15 Best Performing Medical Device Manufacture Companies Of 2020

    New medical innovations are emerging day by day and are playing a major role in the health care sector. Much of the credit for these new technological innovations go to the medical devices industry. Technological advancement is continuously changing the medical devices industry. The medical devices that provide and analyze data of patients within minutes are aiding the healthcare organizations to improve patients outcomes, lower costs, and enhance efficiency.

    2020 is the year of challenges and opportunities for many industries including the medical devices industry. The medical device industry is growing with fast speed and it doesn’t seem like it is going to be slowing down anytime soon. The growth in the medical devices industry has occurred because of increasing severe disease with the increasing population. These new diseases need new treatments that can reduce the symptoms in patients. The medical devices industry is important to patients for many reasons. Medical devices companies engaged in the innovations of new technologies that are helpful for patients with chronic diseases.

    Here are the top 15 leading players in the medical devices industry you should be holding right now:

    SmileDirectClub Inc. (NASDAQ: SDC)

    SmileDirectClub Inc. (NASDAQ: SDC) last closed at $11.27, in a 52-week range of $3.64 to $21.10. Analysts have a consensus price target of $10.08. SmileDirectClub Inc. (SDC) has partnered with Meredith Corporation (MDP) to introduce Telehealth Explained. Telehealth Explained is the new platform aimed to educate consumers about the many benefits of telehealth for physical, mental, and dental health.  SmileDirectClub Inc.’s market cap has remained high, hitting $4.66 billion at the time of writing.

    CHF Solutions Inc. (CHFS)

    CHF Solutions Inc. (CHFS) stock soar by 5.85% to $0.32. CHF Solutions Inc. (CHFS) has earlier disclosed that it has received 180-extension to meet the Nasdaq minimum bid price requirement. The company has now the time since February 24, 2021, to meet all the requirements.  CHFS has earlier hosted the interactive, physician-led webinar to discuss “Precision Medicine for the Treatment of Fluid Overload in Patients with Acute Heart Failure.” CHF Solutions has a 52-weeks low and high range of $0.28 and a low range of $2.92.

    Abbott Laboratories (NYSE: ABT)

    Abbott Laboratories (NYSE: ABT) stock soar by 2.89% to $105.81. The most recent rating by Goldman, on June 01, 2020, is at a Sell. Abbott Laboratories (ABT) has earlier disclosed that it has initiated the LIFE-BTK clinical trial to evaluate the safety and effectiveness of the company’s new Esprit™ BTK Everolimus-Eluting Resorbable Scaffold System.  ABT has a 52-weeks low and high range of $61.61 and $114.19, respectively. It has a market cap of $189.80 billion at the time of writing.

    Avinger Inc. (NASDAQ: AVGR)

    Avinger Inc. (NASDAQ: AVGR) Shares headed rising, higher as much as 3.70%. The most recent rating by Ladenburg Thalmann, on March 09, 2018, is at a Buy. Avinger Inc. (AVGR) has earlier disclosed that the underwriter of its earlier revealed underwritten public offering has practiced, in full, their option to purchase an additional 1,000,000 shares of the Company’s common stock at a price of $0.47 per share. Avinger Inc.’s market capitalization has remained high, hitting $36.67 million at the time of writing.

    InspireMD Inc. (AMEX: NSPR)

    InspireMD Inc. (AMEX: NSPR) fall -7.23% after losing more than -$0.02 on Wednesday. InspireMD Inc. has disclosed that it has received the FDA approval to proceed with a pivotal study of the CGuard Carotid Stent System, CARENET-III, for prevention of stroke in patients in the United States.  The FDA approval of Investigational Device Exemption (IDE) has been proved to be useful for the company as it is now able to conduct the trial to check the potential of CGuard EPS against carotid artery disease.

    BIOLASE Inc. (NASDAQ: BIOL)

    BIOLASE Inc. (NASDAQ: BIOL) last closed at $0.30, in a 52-week range of $0.21 to $1.16. BIOLASE Inc. (BIOL) has disclosed that Todd Norbe, President and CEO, and John Beaver, COO, and CFO, will be providing an overview of the Company, as well as recent progress and achievements at the Colliers & Co.  Institutional Investor Conference on Thursday, September 10, 2020. BIOLASE Inc. has a market capitalization of $26.66 million at the time of writing.

    Stryker Corporation (NYSE: SYK)

    Stryker Corporation (NYSE: SYK) stock soar by 2.66% to $205.41. The most recent rating by Barclays, on April 13, 2020, is at an Underweight. Stryker Corporation (SYK) has earlier revealed that it will take part in the Morgan Stanley 18th Annual Virtual Global Healthcare Conference on Tuesday, September 15, 2020. This company’s market capitalization has remained high, hitting $77.31 billion at the time of writing.

    Livongo Health Inc. (NASDAQ: LVGO)

    Livongo Health Inc. (NASDAQ: LVGO) last closed at $128.03, in a 52-week range of $15.12 to $150.00. Analysts have a consensus price target of $130.41. Livongo Health Inc. (LVGO) disclosed that executives of Livongo Health and the executives from Teladoc Health will be participating in the following upcoming investor conferences. It had a trading volume of 1.72 million as compared to the average volume of 4.89 million.

    Boston Scientific Corporation (NYSE: BSX)

    Boston Scientific Corporation (NYSE: BSX) shares headed rising, higher as much as 1.49% after Boston Scientific Launches Vercise Genus™ DBS System In Europe. The most recent rating by SVB Leerink, on April 22, 2020, is at an Mkt perform. Boston Scientific Corporation (BSX) has a 52-weeks low and high range of $24.10 and $46.62, respectively. It has a market cap of $59.43 billion at the time of writing.

    Medtronic plc (NYSE: MDT)

    Medtronic plc (NYSE: MDT) rose 1.99% after gaining more than $2.08 on Wednesday. Medtronic Receives Breakthrough Device Designation from FDA, Begins Early Feasibility Study for Investigational Intrepid™ Transcatheter Valve System for the Treatment of Tricuspid Valve Regurgitation. Medtronic plc (MDT) has traded up 47.87% from its 52-weeks low and traded down -12.68% from its 52-weeks high.

    Ra Medical Systems Inc. (RMED)

    Ra Medical Systems Inc. (RMED) last closed at $0.25, in a 52-week range of $0.26 to $2.69. Ra Medical Systems to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 16. Ra Medical Systems Inc. (RMED) has traded down -2.46% from its 52-weeks low and traded down 90.57% from its 52-weeks high.

    Hancock Jaffe Laboratories Inc. (NASDAQ: HJLI)

    Hancock Jaffe Laboratories Inc. (NASDAQ: HJLI) shares were trading up 12.80% at $0.41 at the time of writing on Wednesday. Hancock Jaffe Laboratories Inc. (NASDAQ: HJLI) share price went from a low point around $0.21 to briefly over $1.03 in the past 52 weeks, though shares have since pulled back to $0.41. HJLI market cap has remained high, hitting $16.12M at the time of writing.

    Nano-X Imaging Ltd. (NASDAQ: NNOX)

    Nano-X Imaging Ltd. (NASDAQ: NNOX) shares headed rising, higher as much as 7.76% after Nanox Signs Agreement With SPI Medical for the Deployment of 630 Nanox. Its stock has fluctuated between the 52-weeks low of $20.25 and a 52-weeks high range of $43.48. NNOX has moved up 117.33% and 1.24% from its 52-weeks low and high, respectively. Its market capitalization has remained high, hitting $2.08 billion.

    Edwards Lifesciences Corporation (NYSE: EW)

    Edwards Lifesciences Corporation (NYSE: EW) rose 3.26% after gaining more than $2.68 on Wednesday. Edwards Lifesciences Corporation (EW) stock has fluctuated between the 52-weeks low of $51.51 and a 52-weeks high range of $87.79. EW has moved up 64.72% from its 52-weeks low and moved down -3.36% from its 52-weeks high, respectively. Its market capitalization has remained high, hitting $54.00 billion.

    Wright Medical Group N.V. (NASDAQ: WMGI)

    Wright Medical Group N.V. (NASDAQ: WMGI) stock drop by -0.26% to $30.30. The most recent rating by Jefferies, on December 24, 2019, is at a Hold. Wright Medical Group N.V. (WMGI) has a 52-weeks low and high range of $19.04 and $30.66, respectively. It has a market capitalization of $2.92 billion.

  • Hancock Jaffe Laboratories Inc [HJLI] – What next after Bullish breakout?

    Hancock Jaffe Laboratories Inc [HJLI] – What next after Bullish breakout?

    Hancock Jaffe Laboratories Inc [NASDAQ: HJLI] is in a bullish breakout at the moment.  After trading in a range for months, the stock has shot up by 130%. The breakout follows the company’s announcement that follow-up data on two more VenoValve patients showed improvement compared to their condition before the surgery. The two are part of the company’s first human studies in Colombia.

    The company stated that the two patients included an 86-year old male, whose reflux had improved by 62%. The study also found that on the Venous Clinical Severity Scores, the patients showed an improvement of 42%, while pain improved by about 79%. Besides these two patients, the company had reported that 8 other patients had completed the first-in-human trials. Of the eight, seven patients had an over 50% success on Venovalves, VCSS, Reflux, and VAS. Commenting on the success, the company’s CEO Dr Marc H. Glickman said that the results were a major improvement and that they would drive excitement in the world of vascular treatment.

    The treatment will now go to the next step of more monitoring and undergo several tests as required by the FDA.  The company also announced that it expected to file for a pivotal trial in Q1 of 2021.

    What next?

    With the progress that the company has made so far with this treatment, positive sentiment is likely to remain high, until 2021 when it enters the pivotal trial. That’s because approval of this treatment would mean a huge bump in revenues and an increase in the intrinsic value of the stock.

    The stock also stands to benefit from two major market-related factors. The first one is the increased fear of market overvaluation. Since the S&P 500 hit a new high recently, momentum has become more subdued. Investors are looking more into tech, and stocks that have strong growth fundamentals. From this perspective, HJLI offers good prospects that could see it grow revenues long-term, due to the positive progress with regards to the treatment currently undergoing human trials.  This is likely to see more money flow into the stock, especially now that it has broken resistance.

    There is also the possibility of a market-wide rally if a COVID-19 vaccine is found soon. There is growing consensus in the scientific community that a vaccine could be found before the end of 2020. If this happens, a stock with strong momentum such as HJLI could rally even more. Its momentum could be boosted if the vaccine comes out at around the same time as the pivotal trial for the company’s treatment in 2021.

    About Hancock Jaffe Laboratories Inc

    Hancock Jaffe Laboratories Inc is a biotech company that develops tissue solutions for cardiovascular ailments. The company is headquartered in Irvine, California.